// App-Quantinova.ai

3910 : SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes

Researchers

Presenter

  • E. Jodar

Principal Investigators

  • J. Seufert

  • L.H. Damgaard

  • A.G. Holst

  • L.A. Leiter

Medical Centers

  • Hospital Universitario QuirÏŒn Salud Madrid, Facultad de Ciencias de la Salud, Universidad Europea de Madrid, Madrid, Spain

  • University of Freiburg Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

  • Novo NordiskA/S, Soborg, Denmark

  • Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, Ontario, Canada

Locations

  • Spain

  • Germany

  • Denmark

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Semaglutide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved